This study compares a new drug called **soquelitinib** with standard treatments for certain types of blood cancer. The cancers being studied are forms of **T-cell lymphoma**, which is a cancer affecting white blood cells. The study is randomized, meaning participants are randomly assigned to receive either soquelitinib or a standard treatment chosen by their doctor. It is an open-label study, so both the doctors and patients know which treatment is being given.

Participants will be treated for up to two years, or until their cancer worsens or they can't tolerate the treatment. If the cancer progresses while on the standard treatment, participants might switch to soquelitinib.

• **Duration:** The study can last up to 2 years.
• **Participation:** Approximately 150 people will join, and they must be at least 18 years old.
• **Risks:** As with any treatment, there could be side effects, and participants' health must be closely monitored.

Participants should have a life expectancy of more than 12 weeks and have previously tried 1 to 3 other treatments for their cancer.